[go: up one dir, main page]

MX9300014A - Nuevos derivados de 1,2,4-triaminobenceno y procedimiento para su elaboracion. - Google Patents

Nuevos derivados de 1,2,4-triaminobenceno y procedimiento para su elaboracion.

Info

Publication number
MX9300014A
MX9300014A MX9300014A MX9300014A MX9300014A MX 9300014 A MX9300014 A MX 9300014A MX 9300014 A MX9300014 A MX 9300014A MX 9300014 A MX9300014 A MX 9300014A MX 9300014 A MX9300014 A MX 9300014A
Authority
MX
Mexico
Prior art keywords
triaminobenzene
preparation
new derivatives
derivatives
acid addition
Prior art date
Application number
MX9300014A
Other languages
English (en)
Inventor
Hans Reinhold
Dieter Jurgen
Engel Bernhard Kutscher
Emmanuel Polymeropoulos
Stefan Szelenyi
Bernd Nickel
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of MX9300014A publication Critical patent/MX9300014A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/42—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/43—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/40—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Derivados del 1,2,4-triaminobenceno farmacológicamente eficaces y sus sales de adición de ácidos farmacéuticamente compatibles.
MX9300014A 1992-01-08 1993-01-06 Nuevos derivados de 1,2,4-triaminobenceno y procedimiento para su elaboracion. MX9300014A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4200259A DE4200259A1 (de) 1992-01-08 1992-01-08 Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung

Publications (1)

Publication Number Publication Date
MX9300014A true MX9300014A (es) 1993-07-01

Family

ID=6449201

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9300014A MX9300014A (es) 1992-01-08 1993-01-06 Nuevos derivados de 1,2,4-triaminobenceno y procedimiento para su elaboracion.

Country Status (13)

Country Link
US (1) US5384330A (es)
EP (1) EP0554543B1 (es)
JP (1) JP3145220B2 (es)
AT (1) ATE134611T1 (es)
CA (1) CA2086654C (es)
DE (3) DE4200259A1 (es)
DK (1) DK0554543T3 (es)
ES (1) ES2084914T3 (es)
GR (1) GR3019653T3 (es)
LU (1) LU91869I2 (es)
MX (1) MX9300014A (es)
SG (1) SG48046A1 (es)
ZA (1) ZA9311B (es)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
EP0809492A4 (en) * 1995-02-17 2007-01-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
US6005008A (en) * 1996-02-16 1999-12-21 Smithkline Beecham Corporation IL-8 receptor antagonists
US6262113B1 (en) 1996-03-20 2001-07-17 Smithkline Beecham Corporation IL-8 receptor antagonists
US6211373B1 (en) 1996-03-20 2001-04-03 Smithkline Beecham Corporation Phenyl urea antagonists of the IL-8 receptor
KR20000022274A (ko) * 1996-06-27 2000-04-25 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 Il-8 수용체 길항제
AU3499497A (en) 1996-06-27 1998-01-14 Smithkline Beecham Corporation Il-8 receptor antagonists
DE19701694A1 (de) * 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
DE19752748A1 (de) 1997-11-28 1999-06-02 Bayer Ag Substituierte Phenyluracile
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
US6117900A (en) * 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6378671B1 (en) 2000-03-29 2002-04-30 Lord Corporation Magnetically actuated motion control device
TWI287984B (en) 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
WO2002080898A2 (en) * 2001-04-04 2002-10-17 Wyeth Methods for treating hyperactive gastric motility
DE10136046A1 (de) * 2001-07-25 2003-02-13 Viatris Gmbh Verfahren zur Herstellung von 1,2,4-Triaminobenzol-carbamidsäureestern
US7205307B2 (en) 2002-02-14 2007-04-17 Icagen, Inc. Pyrimidines as novel openers of potassium ion channels
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
TWI325414B (en) * 2002-12-27 2010-06-01 Lundbeck & Co As H 1,2,4-triaminobenzene derivatives
AU2003287922B2 (en) * 2002-12-27 2009-12-10 H. Lundbeck A/S 1,2,4-triaminobenzene derivatives useful for treating disorders of the central nervous system
WO2004082677A1 (en) 2003-03-21 2004-09-30 H. Lundbeck A/S Substituted p-diaminobenzene derivatives
EP1631546A1 (en) * 2003-04-25 2006-03-08 H. Lundbeck A/S Sustituted indoline and indole derivatives
US20050089559A1 (en) 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
TWI349666B (en) 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
UA89503C2 (uk) 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
EP2298766B1 (en) 2005-03-03 2013-09-18 H. Lundbeck A/S Pharmaceutical formulations comrpising a substituted pyridine derivative
CA2604759A1 (en) * 2005-04-22 2006-11-02 Wyeth Dihydrobenzofuran derivatives and uses thereof
TW200716583A (en) * 2005-04-22 2007-05-01 Wyeth Corp Crystal forms of {[(2R)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
WO2006116151A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
US7402687B2 (en) * 2005-04-22 2008-07-22 Wyeth Dihydrobenzofuran derivatives and uses thereof
GT200600162A (es) * 2005-04-24 2007-03-14 Metodos para modular la funcion de la vejiga
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
EP1983974A1 (en) 2006-02-07 2008-10-29 H. Lundbeck A/S Use of kcnq-openers for treating or reducing the symptoms of schizophrenia
EP1998781A2 (en) * 2006-03-24 2008-12-10 Wyeth a Corporation of the State of Delaware Treatment of pain
PE20080010A1 (es) * 2006-03-24 2008-03-10 Wyeth Corp Derivados de diazepina para el tratamiento de la depresion y composiciones farmaceuticas que los comprenden
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
KR20090079191A (ko) * 2006-08-23 2009-07-21 밸리언트 파마슈티컬즈 인터내셔널 칼륨 채널 조절제로서 ４-(ｎ-아자사이클로알킬) 아닐리드의 유도체
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
ES2375417T3 (es) * 2006-11-28 2012-02-29 Valeant Pharmaceuticals International Análogos 1,4-diamino bicíclicos de retigabina como moduladores de los canales de potasio.
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
CN101868443A (zh) 2007-09-20 2010-10-20 特拉维夫大学拉莫特有限公司 N-苯基邻氨基苯甲酸衍生物及其用途
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
GB0723794D0 (en) 2007-12-05 2008-01-16 Lectus Therapeutics Ltd Potassium ion channel modulators and uses thereof
US20100323016A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
US20100323015A1 (en) * 2008-07-18 2010-12-23 Biljana Nadjsombati Modified release formulation and methods of use
NZ590885A (en) * 2008-07-18 2013-01-25 Valeant Pharmaceuticals Int A modified release pharmaceutical formulation of retigabine for the treatment of nervous system hyperexcitability
DE102009013613A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Trockenverarbeitung von Retigabin
DE102009013612A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabin-Tabletten, bevorzugt mit modifizierter Freisetzung
DE102009013611A1 (de) 2009-03-17 2010-09-23 Ratiopharm Gmbh Festes Retigabin in nicht-kristalliner Form
WO2011012659A2 (en) 2009-07-28 2011-02-03 Medichem S.A. Diethyl 4-(4-fluorobenzylamino)-1,2-phenylenedicarbamate, and salts thereof
WO2011039369A2 (en) 2009-10-02 2011-04-07 Medichem S.A. Amorphous forms of a 2-amino-4-(4-fluorobenzylamino)phenylcarbamate derivative
JP2013517315A (ja) 2010-01-20 2013-05-16 グラクソ グループ リミテッド 新規組成物
EP2536394A2 (en) 2010-02-19 2012-12-26 Medichem S.A. Stabilized phenylcarbamate derivative in solid state
CN101921195A (zh) * 2010-08-02 2010-12-22 北京德众万全医药科技有限公司 一种瑞替加滨中间体的简单合成方法
WO2012098075A1 (en) * 2011-01-18 2012-07-26 Glaxo Group Limited Process for the preparation of retigabine
CN102241608A (zh) * 2011-05-12 2011-11-16 天津市汉康医药生物技术有限公司 瑞替加滨化合物及其组合物
WO2013011518A1 (en) 2011-07-21 2013-01-24 Arch Pharmalabs Limited Process for the preparation of retigabine of the formula i and pharmaceutically acceptable salts thereof
CN103073455B (zh) * 2011-10-25 2015-08-19 中国科学院上海药物研究所 一类新型的kcnq钾通道激动剂、其制备方法和用途
CN102531966B (zh) * 2011-12-23 2013-07-24 山东创新药物研发有限公司 瑞替加滨的晶型d及其制备方法
ITMI20120137A1 (it) * 2012-02-02 2013-08-03 Olon Spa Procedimento ed intermedi per la preparazione di retigabina
CN103373941B (zh) * 2012-04-11 2016-08-17 浙江九洲药物科技有限公司 瑞替加滨及其中间体的制备方法
AU2013257209B2 (en) * 2012-04-30 2016-05-19 Scifluor Life Sciences, Inc Fluorinated 2-amino-4-(benzylamino)phenylcarbamate derivatives
WO2014023270A1 (en) 2012-08-09 2014-02-13 Zentiva, K.S. Salts or co-crystals of ethyl n-[2-amino-4-[(4-fluorophenyl)methylamino]-phenyl]carbamate
ITMI20121922A1 (it) * 2012-11-12 2014-05-13 Dipharma Francis Srl Procedimento per la preparazione di un composto anticonvulsivante
CN103193657B (zh) * 2013-04-16 2015-08-05 石家庄度恩医药科技有限公司 一种合成依佐加滨中间体的方法
CN103664678B (zh) * 2013-11-06 2015-10-28 河北科技大学 一种n1-(4-氟苄基)-4-硝基苯基-1,3-二胺的中间体及其制备方法
CN105017085B (zh) * 2014-04-28 2018-06-29 中国科学院上海药物研究所 一类kcnq钾通道激动剂、其制备方法和用途
US10526280B2 (en) 2014-11-13 2020-01-07 University of Pittsburgh—of the Commonwealth System of Higher Education (2-amino-4-(arylamino)phenyl carbamates
RU2018147263A (ru) * 2016-06-10 2020-07-10 Сайфлуор Лайф Сайенсиз, Инк Фторированные 2-амино-4-(замещенные амино)фенилкарбаматные производные
DK3554490T3 (da) 2016-12-16 2022-02-28 Idorsia Pharmaceuticals Ltd Farmaceutisk kombination omfattende en calciumkanalblokker type T
WO2019014547A1 (en) 2017-07-14 2019-01-17 Texas Tech University System FUNCTIONALIZED PYRIDINE CARBAMATES HAVING ENHANCED NEUROPROTECTOR ACTIVITY
US11427531B2 (en) 2017-10-09 2022-08-30 Ramot At Tel-Aviv University Ltd. Modulators of potassium ion and TRPV1 channels and uses thereof
EP3724163A4 (en) 2017-12-13 2021-07-28 SciFluor Life Sciences, Inc. FLUORINE DERIVATIVES 4- (AMINO SUBSTITUTE) PHENYL CARBAMATE
WO2019203951A1 (en) 2018-04-20 2019-10-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Selective potassium channel agonists
WO2020157126A1 (en) 2019-01-29 2020-08-06 Università degli Studi di Salerno Modulators of potassium ion channels and uses thereof
AU2020380961A1 (en) 2019-11-08 2022-05-26 Xenon Pharmaceuticals Inc. Methods of treating depressive disorders
MX2022006472A (es) 2019-12-02 2022-09-09 Xenon Pharmaceuticals Inc Formulacion pediatrica de liberacion inmediata del abridor de canales de potasio ezogabina.
MX2023009314A (es) 2021-02-09 2023-08-16 Xenon Pharmaceuticals Inc Apertura del canal de potasio dependiente de voltaje para usarse en el tratamiento de la anhedonia.
CN117295711A (zh) * 2021-03-19 2023-12-26 艾可斯外扎根股份有限公司 Kv7通道开放剂的前药
EP4433472A1 (en) 2021-11-19 2024-09-25 Icagen, LLC Pyridine compounds as kv7.2 enhancers
CR20240203A (es) 2021-11-19 2024-07-09 Icagen Llc Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2
WO2023121992A1 (en) 2021-12-22 2023-06-29 Icagen, Llc Cyclopropyl compounds
CN116478068A (zh) 2022-01-14 2023-07-25 中国科学院上海药物研究所 一种高选择性kcnq4钾通道激动剂、其制备方法和用途
CN118829626A (zh) 2022-02-15 2024-10-22 伊卡根有限责任公司 新颖双环戊烷衍生物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3337593A1 (de) * 1982-10-27 1984-05-03 Degussa Ag, 6000 Frankfurt 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung
MC2029A1 (fr) * 1988-05-16 1990-04-25 Asta Pharma Ag (n-heterocyclyl)-3 diamino-2,6 pyridines substituees et leurs n-oxydes,preparation de ces composes et leur application comme medicaments
DE3917113A1 (de) * 1989-05-26 1990-11-29 Schwarzkopf Gmbh Hans Verfahren zur selektiven herstellung von n(pfeil hoch)4(pfeil hoch)-substituierten 1,4-diamino-2-nitrobenzolen
GB8921792D0 (en) * 1989-09-27 1989-11-08 May & Baker Ltd New compositions of matter
US5220059A (en) * 1990-04-19 1993-06-15 Abbott Laboratories Lipoxygenase-inhibiting compounds derived from non-steroidal antiinflammatory carboxylic acids

Also Published As

Publication number Publication date
DE4200259A1 (de) 1993-07-15
CA2086654C (en) 2003-09-23
DK0554543T3 (da) 1996-03-18
ES2084914T3 (es) 1996-05-16
DE59205496D1 (de) 1996-04-04
GR3019653T3 (en) 1996-07-31
ZA9311B (en) 1993-08-05
JP3145220B2 (ja) 2001-03-12
EP0554543A3 (en) 1993-10-27
SG48046A1 (en) 1998-04-17
LU91869I2 (fr) 2011-11-14
JPH05345752A (ja) 1993-12-27
ATE134611T1 (de) 1996-03-15
EP0554543A2 (de) 1993-08-11
DE122011100044I1 (de) 2012-01-19
US5384330A (en) 1995-01-24
CA2086654A1 (en) 1993-07-09
EP0554543B1 (de) 1996-02-28

Similar Documents

Publication Publication Date Title
MX9300014A (es) Nuevos derivados de 1,2,4-triaminobenceno y procedimiento para su elaboracion.
ES2138691T3 (es) Procedimiento para la obtencion de derivados de n-acil-5-fluorocitidina.
ES2175127T3 (es) Derivados de la quinazolina y su uso.
NO985711D0 (no) Farmas°ytikum for behandling av neurologiske og neuropsykiatriske mangler
MX9301348A (es) Nuevos compuestos que tienen actividad farmacologica, proceso para su preparacion y composicion farmaceutica que los comprende.
ES2184960T3 (es) Nuevas pirimidin-4-onas-(5,6)-heteroaril condensadas 2,3 disustituidas.
ES510348A0 (es) "procedimiento de preparacion de nuevos derivados 3,4-dihidro-5h-2,3-benzodiazepinos y de sus sales de adicion acidas farmaceuticamente aceptables".
ES2144239T3 (es) Derivados de vitamina d con sustituyentes en c-25, procedimiento para su preparacion, productos intermedios y la utilizacion para la preparacion de medicamentos.
ES2036259T3 (es) Un procedimientos para la preparacion de agentes antiinflamatorios.
ES2062137T3 (es) Utilizacion de 5'-deoxi-5'-metil-tioadenosina, s-adenosilmetionina y sus sales para la preparacion de composiciones farmaceuticas reductoras de seborrea.
SE9300758D0 (sv) Process for the production of clavulanic acid
ES2135722T3 (es) 1,5-benzodiacepinas 5-heterociclicas moduladoras de la cck o de la gastrina.
ES2043943T3 (es) Procedimiento para la preparacion de compuestos con actividad analgesica central.
ES534859A0 (es) Procedimiento para la obtencion de derivados de 1-(4'-alquilsulfonilfenil)-2-amino-1,3-propandiol n-substituidos
ES2135500T3 (es) Producto farmaceutico para el tratamiento de trastornos de la piel.
ES2118248T3 (es) Esteres y amidas de 9-cloro-prostaglandina y su empleo para preparar medicamentos.
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
DE69104608D1 (de) Pharmazeutische Zubereitungen, Clavulansäure enthaltend, für die Behandlung der Periodontitis.
PT83253B (pt) Processo para a preparacao de p-acilaminobenzamidas
NO880922D0 (no) Fremgangsmaate for fremstilling av farmakologisk aktive benzodioksolderivater.
ES2032476T3 (es) Un procedimiento para preparar nuevos derivados de 2-anilinotiazolina.
ES2065855B1 (es) Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
SE9000948D0 (sv) New use
ES2147576T3 (es) Utilizacion del efaroxan y de sus derivados para la preparacion de un medicamento destinado al tratamiento de la enfermedad de parkinson.
ES2184121T3 (es) Formulacion para el tratamiento y/o profilaxis de la demencia.